News Room
News and updates about Bioscan
--------
Bioscan R&D Center Dijon France
--------
BioFLECT selected as one of the Top 10 Innovations of 2011 by The Scientist magazine
Bioscan's new 360-degree tomographic optical imager, BioFLECT, was awarded 2nd place in The Scientist's Top 10 Innovations of 2011. BioFLECT uses a rotating ring of high-sensitivity photodetectors with a wide dynamic range, which permits whole body, deep tissue imaging to generate a full 3D scan of fluorescent markers in live animals.
Read The Scientist's press release regarding the Top 10 Innovations of 2011 at http://www.prweb.com/releases/2012/1/prweb9053798.htm
--------
Bioscan Featured in Bioscience Technology Online's Cover Story
Bioscan's Vice President for Marketing and Business Development, Alex Kleinman, was quoted in Bioscience Technology Online's August 2011 cover story discucssing the advantages of in vivo imaging, with a focus on optical products and servics. Read more
--------
Eckert & Ziegler acquires the Analytic Instrumentation and Radiochemistry Equipment Business from American market leader Bioscan, Inc.
Berlin, Germany and Washington, DC, USA, 01 July 2011. - Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), specialists in radioactive pharmaceuticals and their production technology, has entered into an agreement with Bioscan Inc., located in Washington, DC, to acquire its radiopharmaceutical equipment business. The transaction involves both analytical instruments used in quality assurance of radioactive pharmaceuticals and automated radiopharmaceutical synthesis units. Such equipment is used worldwide in the production of radiolabeled molecular imaging agents used in nuclear medicine. Read more
Bioscan's SPECT/CT in-vivo preclinical imaging system highlighted on French Television
Bioscan's SPECT/CT in-vivo preclinical imaging system was featured in a recent news segment on nanoparticles and cell therapeutrics. The broadcast highlighted the work of Dr. Claire Bilottey, Pr. Marc Janier & Pr. Frederic Berard, who are affiliated with CHU LYon/Universite Claude Bernard Lyon 1. Watch the video
--------
Bioscan's Fabrice Chaumard discusses the Intergrated Magnetic resonance And Positron emission Tomography in Preclinical Imaging project (IMAPPI)
Bioscan's European Director, Fabrice Chaumard, recently sat down to discuss the IMAPPI project, which will culuminate in the commercilization and production of an interegrated PET/MRI system for use in in-vivo preclinical imaging applications. Watch the video
--------
Bioscan receives major grant from French government for development of an integrated preclinical PET/MRI system
In the framework of its "Equipements d’excellence” initiative, the French Commissariat Général à l'Investissement has granted €7.3 million for the Integrated Magnetic resonance And Positron emission tomography in Preclinical Imaging project (IMAPPI)
DIJON, BURGANDY, FRANCE AND WASHINGTON, DC, US – March 3, 2011. Bioscan, a leading supplier of preclinical imaging systems, including PET/CT and SPECT/CT modalities, recently announced that it will develop a combined PET/MRI system for in-vivo animal imaging applications supported by a grant from the French Government. Bioscan will serve as the lead preclinical imaging systems provider in a consortium of eight partners, all located in the biomedical imaging cluster of excellence in Dijon, France. The total value of the grant for the PET/MRI development project is €7.3 million. Read more
Bioscan’s NanoSPECT/CT enables a landmark study on the in-vivo use of nanotubes for organ-specific therapeutics and diagnostics
WASHINGTON, DC – June 6, 2010. Bioscan, Inc. (Washington, DC) today announced the publication of the first in-vivo application of functionalized sealed carbon nanotubes filled with a radionuclide without prompting cargo release. The stability and biocompatibility of the capsule together with the radioactive payload allows in-vivo imaging of disease models and delivery of a high-density radiodose. Published in the May 2010 issue of Nature Materials under the title “Filled and glycosylated carbon nanotubes for in vivo radioemitter localization and imaging”, the publication envisages that that this work will contribute to the development of organ-specific therapeutics and diagnostics. Read more
Bioscan releases NanoSPECT/CTPlus to extend the performance and functionality of its popular pre-clinical SPECT/CT systems
Real-time GPU-based CT reconstruction and user-selectable circular, helical and stationary SPECT scanning further raise the bar in pre-clinical SPECT imaging
WASHINGTON, DC and SALT LAKE CITY UT – June 6, 2010. Bioscan, Inc. (Washington, DC) announced today the launch of the NanoSPECT/CTPlus in-vivo single photon emission (SPECT) platform. Based on its highly successful NanoSPECT/CT system, the NanoSPECT/CTPlus platform has been enhanced with a number of unique features including rotational, helical and stationary SPECT scanning and real-time GPU-based CT reconstruction. Developed in collaboration with its manufacturer, Mediso Medical Imaging systems, the NanoSPECT/CTPlus features the latest in multi-pinhole SPECT imaging technology, computer hardware, and image reconstruction and processing software. Read more
Bioscan has started routine delivery of its new high-definition pre-clinical PET/CT imaging system
WASHINGTON, DC – June 6, 2010. Bioscan, Inc. announced today that it has begun North American and European shipments of its high-definition pre-clinical NanoPET/CT system. Since the introduction of this in-vivo animal imaging system in North America at last year’s SNM conference (Washington, June 2009), sales of this groundbreaking PET/CT design have increased, and Bioscan is currently making deliveries against its substantial backlog of systems. First installations are at renowned academic institutions including King’s College-University of London, Cambridge University, the Longwood SAIF facility of Harvard Medical School and the French National Institute of Health and Medical Research in Grenoble. Additional installations at renowned academic institutions and pharmaceutical companies at both sides of the Atlantic will follow. Read more
